PA
AMLX icon

Perceptive Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Perceptive Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,679,125
Closed -$4.77M – 113
2024
Q1 		$4.77M Buy
+1,679,125
New +$22M 0.08% 88

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors's AMLX Position: Q1 2026 in Review

Perceptive Advisors held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 8,284,882 shares worth $115M. The position accounts for 2.25% of the portfolio, ranked #13.

Perceptive Advisors first reported a position in AMLX in Q1 2022 and has held it in 16 quarters since. The position peaked at $225M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Perceptive Advisors held 8,284,882 shares of Amylyx Pharmaceuticals worth $115M as of Q1 2026.
  • Perceptive Advisors left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
  • Amylyx Pharmaceuticals made up 2.25% of Perceptive Advisors's portfolio in Q1 2026, its #13 holding.
  • Perceptive Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Perceptive Advisors's Amylyx Pharmaceuticals position peaked at $225M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.